Press release
Frontotemporal Dementia Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Prevail Therapeutics, Coya Therapeutics, Alector Inc., Passage Bio, WaVe life Sciences, and others.
Frontotemporal Dementia Pipeline
In the Frontotemporal Dementia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Frontotemporal Dementia NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Frontotemporal Dementia Pipeline treatment landscape of the report, click here @ Frontotemporal Dementia Pipeline Outlook- https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Frontotemporal Dementia Pipeline Report
• DelveInsight's Frontotemporal Dementia Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
• The leading companies are working in the Frontotemporal Dementia market include Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others.
• Promising Frontotemporal Dementia Pipeline Therapies in the various stages of development include DNL593, Methylprednisolone, Sirolimus, PR006, PBFT02, AL001, TRx0237, Galantamine Hydrobromide, florbetapir 18F, Flortaucipir F18, Memantine Hydrochloride, and others.
• On April 2023, Denali Therapeutics Inc. announced a study of phase 1 & 2 clinical trials for DNL593. This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period.
• On April 2023, Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for Methylprednisolone and Sirolimus. Study PRV-FTD101 is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal PR006 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Three escalating dose (low dose, medium dose and high dose) cohorts are planned. The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of PR006 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will follow up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.
Frontotemporal Dementia Overview
Frontotemporal dementia (FTD) or frontotemporal degeneration refers to a group of disorders caused by progressive nerve cell loss in the brain's frontal lobes (the areas behind your forehead) or its temporal lobes (the regions behind your ears).
For further information, refer to the detailed Frontotemporal Dementia Unmet Needs, click here for Frontotemporal Dementia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Frontotemporal Dementia Emerging Drugs Profile
PR 006: Prevail Therapeutics
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD.PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN.
Latozinemab: Alector
AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.AL001 is being developed in collaboration with GSK.
PBFT-02: Passage Bio
Passage Bio, gene therapy product candidate, PBFT02, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient's cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently the product is in Phase I/II for the treatment of Frontotemporal Dementia.
WVE-004: WaVe life Sciences
WVE-004 is an investigational variant-selective silencing candidate designed to selectively target the transcript variants containing a hexanucleotide repeat expansion (G4C2) in the C9orf72 gene, while sparing the healthy C9orf72 protein. G4C2 expansions are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD.
EXO-050: Coya Therapeutics
EXO 050, is the lead drug candidate of Coya Therapeutics for the treatment of FTD. Currently, the drug is in Pre-Clinical stage of development for the treatment of FTD. .
Frontotemporal Dementia Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Frontotemporal Dementia. The Frontotemporal Dementia companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.
Request a sample and discover the recent advances in Frontotemporal Dementia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Frontotemporal Dementia Segmentation- https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Frontotemporal Dementia Drugs and Companies
• DNL593: Denali Therapeutics Inc.
• Methylprednisolone: Eli Lilly and Company
• PBFT02: Passage Bio Inc.
Frontotemporal Dementia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Frontotemporal Dementia Therapeutics Market include-
Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others.
Dive deep into rich insights for drugs for Frontotemporal Dementia Syndrome Pipeline, click here for Frontotemporal Dementia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Frontotemporal Dementia Pipeline Report
• Coverage- Global
• Companies- Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others.
• Therapies- DNL593, Methylprednisolone, Sirolimus, PR006, PBFT02, AL001, TRx0237, Galantamine Hydrobromide, florbetapir 18F, Flortaucipir F18, Memantine Hydrochloride, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Frontotemporal Dementia Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Frontotemporal Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Frontotemporal Dementia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Latozinemab: Alector
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. PR 006 : Prevail Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EXO-050: Coya Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Frontotemporal Dementia Key Companies
21. Frontotemporal Dementia Key Products
22. Frontotemporal Dementia- Unmet Needs
23. Frontotemporal Dementia- Market Drivers and Barriers
24. Frontotemporal Dementia- Future Perspectives and Conclusion
25. Frontotemporal Dementia Analyst Views
26. Frontotemporal Dementia Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Frontotemporal Dementia Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Prevail Therapeutics, Coya Therapeutics, Alector Inc., Passage Bio, WaVe life Sciences, and others. here
News-ID: 3170815 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Frontotemporal
Frontotemporal Dementia (FTD) Market to Reach USD 4.3 Billion by 2034
Frontotemporal Dementia (FTD) is a rare yet serious group of neurodegenerative disorders characterized by progressive damage to the frontal and temporal lobes of the brain. Unlike Alzheimer's disease, FTD often manifests earlier in life, typically between the ages of 40 and 65, and is marked by personality changes, impaired judgment, and language difficulties. Its early onset and challenging diagnosis make it one of the most complex forms of dementia to…
Frontotemporal Dementia Market Set to Double by 2034, Reaching USD 4.2 Billion
The global FTD market was valued at USD 2.1 billion in 2024 and is projected to reach USD 4.2 billion by 2034, growing at a CAGR of 7.1%. Rising diagnosis rates, growing investment in neurodegenerative disease research, and expanded healthcare access are driving this growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70788
Key Market Highlights
• Increasing recognition of FTD as distinct from Alzheimer's and other dementias.
• Expanding pipeline of clinical trials…
Frontotemporal Dementia Treatment Market - Empathy in Action: Pioneering Frontot …
Newark, New Castle, USA: The "Frontotemporal Dementia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Frontotemporal Dementia Treatment Market: https://www.growthplusreports.com/report/frontotemporal-dementia-treatment-market/8569
This latest report researches the industry structure,…
Frontotemporal Dementia Treatment Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "Frontotemporal Dementia Treatment Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly studies…
Frontotemporal Disorder Treatment Market Size, Share, Impressive Industry Growth …
The global Frontotemporal Disorder treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising orphan drug development initiatives by the FDA, new product launches and the growing geriatric population are some of the key factors contributing to the growth of the global Frontotemporal Disorder treatment market. According to the World Health Organization, in 2019 around 50 million people are living with dementia and the number…
Improvement In Cognitive Empathy to Drive The Frontotemporal Dementia Treatment …
The global Frontotemporal Dementia Treatment Market is bound to witness a CAGR worth satiating In Upcoming Years. In the era of cloud computing, the cloud revolution is there to break the stereotypes. Several key stakeholders are going for cloud hosting solutions providers to enhance their accounting services. This migration to cloud technology is making way for the enterprises to simplify their daily tasks, that too, conveniently and cost-effectively. As such,…
